BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 15578712)

  • 1. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
    Eary JF; Conrad EU; O'Sullivan J; Hawkins DS; Schuetze SM; O'Sullivan F
    J Bone Joint Surg Am; 2014 Jan; 96(2):152-8. PubMed ID: 24430415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
    Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
    Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
    Andreou D; Boldt H; Pink D; Jobke B; Werner M; Schuler M; Reichardt P; Tunn PU
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1076-83. PubMed ID: 24519553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
    Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Elashoff D; Chow K; Evilevitch V; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
    Clin Cancer Res; 2009 Apr; 15(8):2856-63. PubMed ID: 19351756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
    Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
    Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.
    Weitz J; Antonescu CR; Brennan MF
    J Clin Oncol; 2003 Jul; 21(14):2719-25. PubMed ID: 12860950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
    Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
    Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
    Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
    Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
    Eilber FC; Rosen G; Eckardt J; Forscher C; Nelson SD; Selch M; Dorey F; Eilber FR
    J Clin Oncol; 2001 Jul; 19(13):3203-9. PubMed ID: 11432887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
    Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
    Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
    Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
    Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study.
    Tateishi U; Kawai A; Chuman H; Nakatani F; Beppu Y; Seki K; Miyake M; Terauchi T; Moriyama N; Kim EE
    Clin Nucl Med; 2011 Jul; 36(7):526-32. PubMed ID: 21637052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
    el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
    Eary JF; O'Sullivan F; Powitan Y; Chandhury KR; Vernon C; Bruckner JD; Conrad EU
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1149-54. PubMed ID: 12192559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?
    Posch F; Leitner L; Bergovec M; Bezan A; Stotz M; Gerger A; Pichler M; Stöger H; Liegl-Atzwanger B; Leithner A; Szkandera J
    Clin Orthop Relat Res; 2017 May; 475(5):1427-1435. PubMed ID: 28083752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.